Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agent...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Pharmaceuticals (Basel, Switzerland) Ročník 14; číslo 12; s. 1243
Hlavní autori:	Bobrovs, Raitis, Kanepe, Iveta, Narvaiss, Nauris, Patetko, Liene, Kalnins, Gints, Sisovs, Mihails, Bula, Anna L., Grinberga, Solveiga, Boroduskis, Martins, Ramata-Stunda, Anna, Rostoks, Nils, Jirgensons, Aigars, Tars, Kaspars, Jaudzems, Kristaps
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	Switzerland MDPI AG 30.11.2021 MDPI
Predmet:	Amino acids antiviral drugs Binding sites Coronaviruses COVID-19 Enzymes Epidemics high-throughput virtual screening Hydrogen bonds Immune system Ligands Middle East respiratory syndrome MTase inhibitors nsp14 nsp16 Respiratory diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 antiviral drugs SARS-CoV-2 nsp14 high-throughput virtual screening MTase inhibitors nsp16
ISSN:	1424-8247, 1424-8247
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents. Here, we report results from high-throughput virtual screening against these two enzymes. The docking of seven million commercially available drug-like compounds and S-adenosylmethionine (SAM) co-substrate analogues against both MTases resulted in 80 virtual screening hits (39 against nsp14 and 41 against nsp16), which were purchased and tested using an enzymatic homogeneous time-resolved fluorescent energy transfer (HTRF) assay. Nine compounds showed micromolar inhibition activity (IC50 < 200 μM). The selectivity of the identified inhibitors was evaluated by cross-checking their activity against human glycine N-methyltransferase. The majority of the compounds showed poor selectivity for a specific MTase, no cytotoxic effects, and rather poor cell permeability. Nevertheless, the identified compounds represent good starting points that have the potential to be developed into efficient viral MTase inhibitors.
AbstractList	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents. Here, we report results from high-throughput virtual screening against these two enzymes. The docking of seven million commercially available drug-like compounds and S-adenosylmethionine (SAM) co-substrate analogues against both MTases resulted in 80 virtual screening hits (39 against nsp14 and 41 against nsp16), which were purchased and tested using an enzymatic homogeneous time-resolved fluorescent energy transfer (HTRF) assay. Nine compounds showed micromolar inhibition activity (IC50 < 200 μM). The selectivity of the identified inhibitors was evaluated by cross-checking their activity against human glycine N-methyltransferase. The majority of the compounds showed poor selectivity for a specific MTase, no cytotoxic effects, and rather poor cell permeability. Nevertheless, the identified compounds represent good starting points that have the potential to be developed into efficient viral MTase inhibitors. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents. Here, we report results from high-throughput virtual screening against these two enzymes. The docking of seven million commercially available drug-like compounds and S-adenosylmethionine (SAM) co-substrate analogues against both MTases resulted in 80 virtual screening hits (39 against nsp14 and 41 against nsp16), which were purchased and tested using an enzymatic homogeneous time-resolved fluorescent energy transfer (HTRF) assay. Nine compounds showed micromolar inhibition activity (IC50 < 200 μM). The selectivity of the identified inhibitors was evaluated by cross-checking their activity against human glycine N-methyltransferase. The majority of the compounds showed poor selectivity for a specific MTase, no cytotoxic effects, and rather poor cell permeability. Nevertheless, the identified compounds represent good starting points that have the potential to be developed into efficient viral MTase inhibitors.The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents. Here, we report results from high-throughput virtual screening against these two enzymes. The docking of seven million commercially available drug-like compounds and S-adenosylmethionine (SAM) co-substrate analogues against both MTases resulted in 80 virtual screening hits (39 against nsp14 and 41 against nsp16), which were purchased and tested using an enzymatic homogeneous time-resolved fluorescent energy transfer (HTRF) assay. Nine compounds showed micromolar inhibition activity (IC50 < 200 μM). The selectivity of the identified inhibitors was evaluated by cross-checking their activity against human glycine N-methyltransferase. The majority of the compounds showed poor selectivity for a specific MTase, no cytotoxic effects, and rather poor cell permeability. Nevertheless, the identified compounds represent good starting points that have the potential to be developed into efficient viral MTase inhibitors. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the SARS-CoV-2 mRNA cap methyltransferases (MTases) nsp14 and nsp16, which are emerging targets for the development of broad-spectrum antiviral agents. Here, we report results from high-throughput virtual screening against these two enzymes. The docking of seven million commercially available drug-like compounds and S-adenosylmethionine (SAM) co-substrate analogues against both MTases resulted in 80 virtual screening hits (39 against nsp14 and 41 against nsp16), which were purchased and tested using an enzymatic homogeneous time-resolved fluorescent energy transfer (HTRF) assay. Nine compounds showed micromolar inhibition activity (IC < 200 μM). The selectivity of the identified inhibitors was evaluated by cross-checking their activity against human glycine N-methyltransferase. The majority of the compounds showed poor selectivity for a specific MTase, no cytotoxic effects, and rather poor cell permeability. Nevertheless, the identified compounds represent good starting points that have the potential to be developed into efficient viral MTase inhibitors.
Author	Ramata-Stunda, Anna Tars, Kaspars Jaudzems, Kristaps Patetko, Liene Kalnins, Gints Kanepe, Iveta Boroduskis, Martins Bula, Anna L. Narvaiss, Nauris Bobrovs, Raitis Grinberga, Solveiga Jirgensons, Aigars Rostoks, Nils Sisovs, Mihails
AuthorAffiliation	2 Faculty of Biology, University of Latvia, Jelgavas 1, LV-1004 Riga, Latvia; liene.patetko@gmail.com (L.P.); martins.boroduskis@lu.lv (M.B.); anna.ramata-stunda@lu.lv (A.R.-S.); nils.rostoks@lu.lv (N.R.) 1 Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia; iveta@farm.osi.lv (I.K.); nauris.narvaiss@osi.lv (N.N.); anna.lina.bula@osi.lv (A.L.B.); solveiga@osi.lv (S.G.); aigars@osi.lv (A.J.); kristaps.jaudzems@osi.lv (K.J.) 3 Latvian Biomedical Research and Study Centre, Ratsupites 1 k1, LV-1067 Riga, Latvia; gints.kalnins@biomed.lu.lv (G.K.); mihails.shishovs@gmail.com (M.S.); kaspars@biomed.lu.lv (K.T.)
AuthorAffiliation_xml	– name: 2 Faculty of Biology, University of Latvia, Jelgavas 1, LV-1004 Riga, Latvia; liene.patetko@gmail.com (L.P.); martins.boroduskis@lu.lv (M.B.); anna.ramata-stunda@lu.lv (A.R.-S.); nils.rostoks@lu.lv (N.R.) – name: 1 Latvian Institute of Organic Synthesis, Aizkraukles 21, LV-1006 Riga, Latvia; iveta@farm.osi.lv (I.K.); nauris.narvaiss@osi.lv (N.N.); anna.lina.bula@osi.lv (A.L.B.); solveiga@osi.lv (S.G.); aigars@osi.lv (A.J.); kristaps.jaudzems@osi.lv (K.J.) – name: 3 Latvian Biomedical Research and Study Centre, Ratsupites 1 k1, LV-1067 Riga, Latvia; gints.kalnins@biomed.lu.lv (G.K.); mihails.shishovs@gmail.com (M.S.); kaspars@biomed.lu.lv (K.T.)
Author_xml	– sequence: 1 givenname: Raitis orcidid: 0000-0002-0221-8658 surname: Bobrovs fullname: Bobrovs, Raitis – sequence: 2 givenname: Iveta surname: Kanepe fullname: Kanepe, Iveta – sequence: 3 givenname: Nauris surname: Narvaiss fullname: Narvaiss, Nauris – sequence: 4 givenname: Liene surname: Patetko fullname: Patetko, Liene – sequence: 5 givenname: Gints surname: Kalnins fullname: Kalnins, Gints – sequence: 6 givenname: Mihails surname: Sisovs fullname: Sisovs, Mihails – sequence: 7 givenname: Anna L. surname: Bula fullname: Bula, Anna L. – sequence: 8 givenname: Solveiga surname: Grinberga fullname: Grinberga, Solveiga – sequence: 9 givenname: Martins surname: Boroduskis fullname: Boroduskis, Martins – sequence: 10 givenname: Anna orcidid: 0000-0003-0097-0931 surname: Ramata-Stunda fullname: Ramata-Stunda, Anna – sequence: 11 givenname: Nils orcidid: 0000-0002-4047-2438 surname: Rostoks fullname: Rostoks, Nils – sequence: 12 givenname: Aigars surname: Jirgensons fullname: Jirgensons, Aigars – sequence: 13 givenname: Kaspars surname: Tars fullname: Tars, Kaspars – sequence: 14 givenname: Kristaps orcidid: 0000-0003-3922-2447 surname: Jaudzems fullname: Jaudzems, Kristaps
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/34959647$$D View this record in MEDLINE/PubMed
BookMark	eNptkktv1DAQgC1URNuFCz8AReKCkAJ-xY4vSNXy6EoFJLb0atmOk3iVtVPbqbT_nmy3hbbi5JH9zefxeE7BkQ_eAvAawQ-ECPhx7BFFGGFKnoETRDEta0z50YP4GJymtIGw4jP5AhwTKirBKD8B7rNLJtzYuCtCW6zPfq3LZbgqcfEjjYgWyje3ESu-29zvhhyVT62NKtli5XunXQ4xFXpXnLuuLy_7GKauH6dcXLmYJzUUaxOt9c53L8HzVg3JvrpbF-D31y-Xy_Py4ue31fLsojSU41xqQVELMRaN4cIoLTgWoqkM0VDbxlhdaU0Rwcgg2FoMGUKGKcyIbVtRM00WYHXwNkFt5BjdVsWdDMrJ240QO6lidmawknEoDMOiqpilVDABITOkgVow1HANZ9eng2uc9HZ_u58bMDySPj7xrpdduJE1h1VF6lnw7k4Qw_VkU5bbud92GJS3YUoSM1QhVENEZvTtE3QTpujnVu0pXCPM53cvwJuHFf0t5f5HZwAeABNDStG20rissgv7At0gEZT7oZH_hmZOef8k5d76H_gP-jHADw
CitedBy_id	crossref_primary_10_1016_j_virusres_2023_199211 crossref_primary_10_1021_acsinfecdis_4c01044 crossref_primary_10_1080_1062936X_2024_2306336 crossref_primary_10_1002_cmdc_202400618 crossref_primary_10_1002_chem_202403390 crossref_primary_10_3390_ijms232213972 crossref_primary_10_1002_slct_202304932 crossref_primary_10_1080_07391102_2023_2297005 crossref_primary_10_1016_j_virol_2023_02_011 crossref_primary_10_1186_s11658_022_00341_9 crossref_primary_10_3390_molecules29102312 crossref_primary_10_1016_j_imu_2022_100886 crossref_primary_10_1021_acsmedchemlett_5c00339 crossref_primary_10_3390_app15094942 crossref_primary_10_1016_j_ejmech_2023_115474 crossref_primary_10_1080_22221751_2023_2204164 crossref_primary_10_1016_j_virol_2024_110042 crossref_primary_10_3390_molecules28020768 crossref_primary_10_3390_molecules27092721 crossref_primary_10_1128_spectrum_00744_22 crossref_primary_10_1007_s11224_022_02019_6
Cites_doi	10.1074/jbc.M114.577353 10.1007/s10822-013-9644-8 10.1016/j.softx.2015.06.001 10.1182/blood-2017-12-818948 10.1016/j.virusres.2014.09.009 10.1080/07391102.2020.1778535 10.1371/annotation/a0dde376-2eb1-4ce3-8887-d29f5ba6f162 10.1128/JVI.00061-13 10.1021/ja00124a002 10.1016/0263-7855(96)00018-5 10.1038/s41467-018-07905-4 10.1021/jm030644s 10.1021/acs.jcim.5b00559 10.1016/j.lfs.2020.118169 10.1128/JVI.00467-06 10.1073/pnas.0808790106 10.1177/2472555220985040 10.1021/ja011423j 10.1016/j.antiviral.2017.06.021 10.1080/10799893.2020.1772298 10.1063/1.2408420 10.1007/978-1-0716-0900-2_1 10.1021/bi00636a032 10.1038/nrmicro.2016.81 10.1021/acsmedchemlett.1c00140 10.1128/JVI.00483-06 10.1038/nrmicro775 10.1126/scisignal.abe1202 10.1021/cb400133j 10.1016/S0021-9258(19)45067-9 10.1002/jcc.20291 10.1021/acsinfecdis.1c00131 10.1101/2021.02.19.424337 10.1016/j.ejmech.2020.112557 10.1038/ncomms2304 10.1063/1.448118 10.1016/j.ccr.2011.06.009 10.1021/acs.jproteome.0c00397 10.1002/jcc.20035 10.3390/molecules24244492 10.1073/pnas.1508686112 10.1038/s41467-020-17495-9 10.1016/S1470-2045(20)30451-4 10.1021/bi00536a011 10.1016/j.jpha.2020.08.002 10.1101/2021.04.07.438812 10.1021/jm300687e 10.1021/ct700200b 10.1080/07391102.2020.1802349 10.1101/2020.04.17.047498 10.1002/prot.20209 10.1042/BCJ20210219
ContentType	Journal Article
Copyright	2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2021 by the authors. 2021
Copyright_xml	– notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2021 by the authors. 2021
DBID	AAYXX CITATION NPM 3V. 7XB 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU COVID DWQXO GNUQQ GUQSH M2O MBDVC PHGZM PHGZT PIMPY PKEHL PQEST PQQKQ PQUKI PRINS Q9U 7X8 5PM DOA
DOI	10.3390/ph14121243
DatabaseName	CrossRef PubMed ProQuest Central (Corporate) ProQuest Central (purchase pre-March 2016) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials - QC ProQuest Central ProQuest One Community College Coronavirus Research Database ProQuest Central ProQuest Central Student ProQuest Research Library Research Library Research Library (Corporate) ProQuest One Academic ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China ProQuest Central Basic MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Basic ProQuest Central Essentials ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Central (Alumni Edition) ProQuest One Community College Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest One Academic UKI Edition ProQuest Central Korea ProQuest Research Library ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	Publicly Available Content Database MEDLINE - Academic CrossRef PubMed
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Pharmacy, Therapeutics, & Pharmacology
EISSN	1424-8247
ExternalDocumentID	oai_doaj_org_article_6709c629556e44969006c3d0b961d7b0 PMC8705538 34959647 10_3390_ph14121243
Genre	Journal Article
GrantInformation_xml	– fundername: Latvian Council of Science grantid: VPP-COVID-2020/1-0014 – fundername: European Regional Development Fund grantid: 1.1.1.2/VIAA/2/18/379
GroupedDBID	--- 2WC 53G 5VS 8G5 AADQD AAFWJ AAYXX ABDBF ABUWG ACGFO ACIHN ACUHS ADBBV AEAQA AFFHD AFKRA AFPKN AFZYC ALMA_UNASSIGNED_HOLDINGS AOIJS AZQEC BAWUL BCNDV BENPR BPHCQ CCPQU CITATION DIK DWQXO EBD ESX GNUQQ GROUPED_DOAJ GUQSH GX1 HH5 HYE IAO IHR ITC KQ8 M2O M48 MK0 MODMG M~E OK1 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC RPM TUS 3V. NPM 7XB 8FK COVID MBDVC PKEHL PQEST PQUKI PRINS Q9U 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c472t-b941f0229dc79cab97299d5c3b0bedceb5bb41321c10fe20611c6a263eff986b3
IEDL.DBID	BENPR
ISICitedReferencesCount	30
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000737083000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1424-8247
IngestDate	Fri Oct 03 12:53:37 EDT 2025 Tue Nov 04 02:00:35 EST 2025 Thu Oct 02 05:20:57 EDT 2025 Mon Jun 30 14:42:59 EDT 2025 Thu Jan 02 22:55:44 EST 2025 Tue Nov 18 22:19:47 EST 2025 Sat Nov 29 07:13:33 EST 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	12
Keywords	antiviral drugs SARS-CoV-2 nsp14 high-throughput virtual screening MTase inhibitors nsp16
Language	English
License	Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c472t-b941f0229dc79cab97299d5c3b0bedceb5bb41321c10fe20611c6a263eff986b3
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0003-0097-0931 0000-0003-3922-2447 0000-0002-4047-2438 0000-0002-0221-8658
OpenAccessLink	https://www.proquest.com/docview/2612812741?pq-origsite=%requestingapplication%
PMID	34959647
PQID	2612812741
PQPubID	2032350
ParticipantIDs	doaj_primary_oai_doaj_org_article_6709c629556e44969006c3d0b961d7b0 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8705538 proquest_miscellaneous_2615118013 proquest_journals_2612812741 pubmed_primary_34959647 crossref_citationtrail_10_3390_ph14121243 crossref_primary_10_3390_ph14121243
PublicationCentury	2000
PublicationDate	20211130
PublicationDateYYYYMMDD	2021-11-30
PublicationDate_xml	– month: 11 year: 2021 text: 20211130 day: 30
PublicationDecade	2020
PublicationPlace	Switzerland
PublicationPlace_xml	– name: Switzerland – name: Basel
PublicationTitle	Pharmaceuticals (Basel, Switzerland)
PublicationTitleAlternate	Pharmaceuticals (Basel)
PublicationYear	2021
Publisher	MDPI AG MDPI
Publisher_xml	– name: MDPI AG – name: MDPI
References	Guiraud (ref_21) 2020; 201 Krafcikova (ref_2) 2020; 11 Bouvet (ref_6) 2014; 289 Konze (ref_18) 2013; 8 ref_57 ref_12 Gounder (ref_20) 2020; 21 Pugh (ref_25) 1982; 21 Bussi (ref_53) 2007; 126 Berendsen (ref_52) 1984; 81 Chen (ref_9) 2009; 106 Scheer (ref_13) 2019; 10 Sterling (ref_40) 2015; 55 Halgren (ref_46) 2004; 47 Basu (ref_30) 2021; 478 Sharma (ref_35) 2020; 259 Daigle (ref_17) 2011; 20 Perveen (ref_31) 2021; 26 Otava (ref_22) 2021; 7 ref_23 Yu (ref_16) 2012; 3 Selvaraj (ref_33) 2021; 39 Stadler (ref_3) 2003; 1 Adzhigirey (ref_43) 2013; 27 Menachery (ref_10) 2014; 194 Falzarano (ref_1) 2016; 14 Stein (ref_19) 2018; 131 ref_29 Lin (ref_27) 2001; 123 Vijayan (ref_24) 2021; 39 Cornell (ref_49) 1995; 117 Lindahl (ref_55) 2005; 26 Yadav (ref_36) 2021; 11 Aouadi (ref_14) 2017; 144 Hess (ref_51) 2008; 4 Abraham (ref_54) 2015; 1–2 Su (ref_8) 2006; 80 Ma (ref_37) 2015; 112 Wang (ref_50) 2004; 25 Minasov (ref_5) 2020; 13 Pakhomova (ref_38) 2004; 57 Humphrey (ref_56) 1996; 14 Kerr (ref_42) 1972; 247 Joseph (ref_7) 2006; 80 ref_47 Liu (ref_15) 2021; 11 ref_45 Pugh (ref_26) 1977; 16 ref_44 ref_41 Wang (ref_4) 2020; Volume 2203 Maurya (ref_34) 2020; 40 Martin (ref_32) 2020; 19 ref_48 Bobrovs (ref_28) 2021; 12 Mysinger (ref_39) 2012; 55 Chen (ref_11) 2013; 87
References_xml	– volume: 289 start-page: 25783 year: 2014 ident: ref_6 article-title: Coronavirus Nsp10, a Critical Co-factor for Activation of Multiple Replicative Enzymes publication-title: J. Biol. Chem. doi: 10.1074/jbc.M114.577353 – volume: 27 start-page: 221 year: 2013 ident: ref_43 article-title: Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments publication-title: J. Comput. Aided. Mol. Des. doi: 10.1007/s10822-013-9644-8 – volume: 1–2 start-page: 19 year: 2015 ident: ref_54 article-title: Gromacs: High performance molecular simulations through multi-level parallelism from laptops to supercomputers publication-title: SoftwareX doi: 10.1016/j.softx.2015.06.001 – volume: 131 start-page: 2662 year: 2018 ident: ref_19 article-title: The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia publication-title: Blood doi: 10.1182/blood-2017-12-818948 – volume: 194 start-page: 191 year: 2014 ident: ref_10 article-title: Coronavirus non-structural protein 16: Evasion, attenuation, and possible treatments publication-title: Virus Res. doi: 10.1016/j.virusres.2014.09.009 – volume: 39 start-page: 4582 year: 2021 ident: ref_33 article-title: Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19 publication-title: J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2020.1778535 – ident: ref_41 doi: 10.1371/annotation/a0dde376-2eb1-4ce3-8887-d29f5ba6f162 – volume: 87 start-page: 6296 year: 2013 ident: ref_11 article-title: Structure-Function Analysis of Severe Acute Respiratory Syndrome Coronavirus RNA Cap Guanine-N7-Methyltransferase publication-title: J. Virol. doi: 10.1128/JVI.00061-13 – volume: 117 start-page: 5179 year: 1995 ident: ref_49 article-title: A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules publication-title: J. Am. Chem. Soc. doi: 10.1021/ja00124a002 – volume: 14 start-page: 33 year: 1996 ident: ref_56 article-title: VMD: Visual molecular dynamics publication-title: J. Mol. Graph. doi: 10.1016/0263-7855(96)00018-5 – volume: 10 start-page: 19 year: 2019 ident: ref_13 article-title: A chemical biology toolbox to study protein methyltransferases and epigenetic signaling publication-title: Nat. Commun. doi: 10.1038/s41467-018-07905-4 – volume: 47 start-page: 1750 year: 2004 ident: ref_46 article-title: Glide: A New Approach for Rapid, Accurate Docking and Scoring. 2. Enrichment Factors in Database Screening publication-title: J. Med. Chem. doi: 10.1021/jm030644s – volume: 55 start-page: 2324 year: 2015 ident: ref_40 article-title: ZINC 15—Ligand Discovery for Everyone publication-title: J. Chem. Inf. Model. doi: 10.1021/acs.jcim.5b00559 – ident: ref_48 – volume: 259 start-page: 118169 year: 2020 ident: ref_35 article-title: Computational guided drug repurposing for targeting 2′-O-ribose methyltransferase of SARS-CoV-2 publication-title: Life Sci. doi: 10.1016/j.lfs.2020.118169 – volume: 80 start-page: 7894 year: 2006 ident: ref_7 article-title: Crystal Structure of Nonstructural Protein 10 from the Severe Acute Respiratory Syndrome Coronavirus Reveals a Novel Fold with Two Zinc-Binding Motifs publication-title: J. Virol. doi: 10.1128/JVI.00467-06 – volume: 106 start-page: 3484 year: 2009 ident: ref_9 article-title: Functional screen reveals SARS coronavirus nonstructural protein nsp14 as a novel cap N7 methyltransferase publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.0808790106 – ident: ref_45 – volume: 26 start-page: 620 year: 2021 ident: ref_31 article-title: A High-Throughput RNA Displacement Assay for Screening SARS-CoV-2 nsp10-nsp16 Complex toward Developing Therapeutics for COVID-19 publication-title: SLAS Discov. Adv. Sci. Drug Discov. doi: 10.1177/2472555220985040 – volume: 123 start-page: 11608 year: 2001 ident: ref_27 article-title: Design of Allele-Specific Protein Methyltransferase Inhibitors publication-title: J. Am. Chem. Soc. doi: 10.1021/ja011423j – volume: 144 start-page: 330 year: 2017 ident: ref_14 article-title: Toward the identification of viral cap-methyltransferase inhibitors by fluorescence screening assay publication-title: Antiviral Res. doi: 10.1016/j.antiviral.2017.06.021 – volume: 40 start-page: 605 year: 2020 ident: ref_34 article-title: Virtual screening, ADME/T, and binding free energy analysis of anti-viral, anti-protease, and anti-infectious compounds against NSP10/NSP16 methyltransferase and main protease of SARS CoV-2 publication-title: J. Recept. Signal Transduct. doi: 10.1080/10799893.2020.1772298 – volume: 126 start-page: 014101 year: 2007 ident: ref_53 article-title: Canonical sampling through velocity rescaling publication-title: J. Chem. Phys. doi: 10.1063/1.2408420 – volume: Volume 2203 start-page: 1 year: 2020 ident: ref_4 article-title: Coronaviruses: An Updated Overview of Their Replication and Pathogenesis publication-title: Coronaviruses. Methods in Molecular Biology doi: 10.1007/978-1-0716-0900-2_1 – volume: 16 start-page: 3928 year: 1977 ident: ref_26 article-title: Inhibition of Newcastle disease virion messenger RNA (guanine-7-)-methyltransferase by analogs of S-adenosylhomocysteine publication-title: Biochemistry doi: 10.1021/bi00636a032 – volume: 14 start-page: 523 year: 2016 ident: ref_1 article-title: SARS and MERS: Recent insights into emerging coronaviruses publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro.2016.81 – volume: 11 start-page: 9848 year: 2021 ident: ref_36 article-title: Docking of fda approved drugs targeting nsp-16, n-protein and main protease of SARS-CoV-2 as dual inhibitors publication-title: Biointerface Res. Appl. Chem. – volume: 12 start-page: 1102 year: 2021 ident: ref_28 article-title: Potent SARS-CoV-2 mRNA Cap Methyltransferase Inhibitors by Bioisosteric Replacement of Methionine in SAM Cosubstrate publication-title: ACS Med. Chem. Lett. doi: 10.1021/acsmedchemlett.1c00140 – ident: ref_47 – volume: 80 start-page: 7902 year: 2006 ident: ref_8 article-title: Dodecamer Structure of Severe Acute Respiratory Syndrome Coronavirus Nonstructural Protein nsp10 publication-title: J. Virol. doi: 10.1128/JVI.00483-06 – volume: 1 start-page: 209 year: 2003 ident: ref_3 article-title: SARS—Beginning to understand a new virus publication-title: Nat. Rev. Microbiol. doi: 10.1038/nrmicro775 – volume: 13 start-page: eabe1202 year: 2020 ident: ref_5 article-title: High-resolution structures of the SARS-CoV-2 2′-O-methyltransferase reveal strategies for structure-based inhibitor design publication-title: Sci. Signal. doi: 10.1126/scisignal.abe1202 – volume: 8 start-page: 1324 year: 2013 ident: ref_18 article-title: An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 publication-title: ACS Chem. Biol. doi: 10.1021/cb400133j – volume: 247 start-page: 4248 year: 1972 ident: ref_42 article-title: Competing methyltransferase systems publication-title: J. Biol. Chem. doi: 10.1016/S0021-9258(19)45067-9 – ident: ref_44 – volume: 26 start-page: 1701 year: 2005 ident: ref_55 article-title: GROMACS: Fast, flexible, and free publication-title: J. Comput. Chem. doi: 10.1002/jcc.20291 – volume: 7 start-page: 2214 year: 2021 ident: ref_22 article-title: The Structure-Based Design of SARS-CoV-2 nsp14 Methyltransferase Ligands Yields Nanomolar Inhibitors publication-title: ACS Infect. Dis. doi: 10.1021/acsinfecdis.1c00131 – ident: ref_23 doi: 10.1101/2021.02.19.424337 – volume: 201 start-page: 112557 year: 2020 ident: ref_21 article-title: Synthesis of adenine dinucleosides SAM analogs as specific inhibitors of SARS-CoV nsp14 RNA cap guanine-N7-methyltransferase publication-title: Eur. J. Med. Chem. doi: 10.1016/j.ejmech.2020.112557 – volume: 3 start-page: 1288 year: 2012 ident: ref_16 article-title: Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors publication-title: Nat. Commun. doi: 10.1038/ncomms2304 – volume: 81 start-page: 3684 year: 1984 ident: ref_52 article-title: Molecular dynamics with coupling to an external bath publication-title: J. Chem. Phys. doi: 10.1063/1.448118 – volume: 20 start-page: 53 year: 2011 ident: ref_17 article-title: Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L Inhibitor publication-title: Cancer Cell doi: 10.1016/j.ccr.2011.06.009 – volume: 19 start-page: 4670 year: 2020 ident: ref_32 article-title: Repurposing of FDA-Approved Toremifene to Treat COVID-19 by Blocking the Spike Glycoprotein and NSP14 of SARS-CoV-2 publication-title: J. Proteome Res. doi: 10.1021/acs.jproteome.0c00397 – volume: 25 start-page: 1157 year: 2004 ident: ref_50 article-title: Development and testing of a general amber force field publication-title: J. Comput. Chem. doi: 10.1002/jcc.20035 – ident: ref_12 doi: 10.3390/molecules24244492 – volume: 112 start-page: 9436 year: 2015 ident: ref_37 article-title: Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex publication-title: Proc. Natl. Acad. Sci. USA doi: 10.1073/pnas.1508686112 – volume: 11 start-page: 3717 year: 2020 ident: ref_2 article-title: Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin publication-title: Nat. Commun. doi: 10.1038/s41467-020-17495-9 – volume: 21 start-page: 1423 year: 2020 ident: ref_20 article-title: Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: An international, open-label, phase 2 basket study publication-title: Lancet Oncol. doi: 10.1016/S1470-2045(20)30451-4 – volume: 21 start-page: 1535 year: 1982 ident: ref_25 article-title: Effects of S-adenosylhomocysteine analogs on vaccinia viral mRNA synthesis and methylation publication-title: Biochemistry doi: 10.1021/bi00536a011 – volume: 11 start-page: 272 year: 2021 ident: ref_15 article-title: Potential treatment with Chinese and Western medicine targeting NSP14 of SARS-CoV-2 publication-title: J. Pharm. Anal. doi: 10.1016/j.jpha.2020.08.002 – ident: ref_29 doi: 10.1101/2021.04.07.438812 – volume: 55 start-page: 6582 year: 2012 ident: ref_39 article-title: Directory of useful decoys, enhanced (DUD-E): Better ligands and decoys for better benchmarking publication-title: J. Med. Chem. doi: 10.1021/jm300687e – volume: 4 start-page: 116 year: 2008 ident: ref_51 article-title: P-LINCS: A parallel linear constraint solver for molecular simulation publication-title: J. Chem. Theory Comput. doi: 10.1021/ct700200b – volume: 39 start-page: 6713 year: 2021 ident: ref_24 article-title: Identification of promising drug candidates against NSP16 of SARS-CoV-2 through computational drug repurposing study publication-title: J. Biomol. Struct. Dyn. doi: 10.1080/07391102.2020.1802349 – ident: ref_57 doi: 10.1101/2020.04.17.047498 – volume: 57 start-page: 331 year: 2004 ident: ref_38 article-title: Glycine N-methyltransferases: A comparison of the crystal structures and kinetic properties of recombinant human, mouse and rat enzymes publication-title: Proteins Struct. Funct. Genet. doi: 10.1002/prot.20209 – volume: 478 start-page: 2481 year: 2021 ident: ref_30 article-title: Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase publication-title: Biochem. J. doi: 10.1042/BCJ20210219
SSID	ssj0057141
Score	2.4015467
Snippet	The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) uses mRNA capping to evade the human immune system. The cap formation is performed by the...
SourceID	doaj pubmedcentral proquest pubmed crossref
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source
StartPage	1243
SubjectTerms	Amino acids antiviral drugs Binding sites Coronaviruses COVID-19 Enzymes Epidemics high-throughput virtual screening Hydrogen bonds Immune system Ligands Middle East respiratory syndrome MTase inhibitors nsp14 nsp16 Respiratory diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2
SummonAdditionalLinks	– databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3da9swEBej7GEvY9_z1g2VjcKgotaHLeux61o62EJYstI3Y8kSMRQnxM4g__1OkpM0o7CXvtnWISTdSXc_fPodQp-ZqzmlgE60sZoIZmsCEIwTJVNHHfgsYwLP7A85GhU3N2p8p9SXzwmL9MBx4U49v5jJmcqy3AqhAMylueF1qlVOa6kDWoeoZwOm4hmcSSpoJCPlAOpPFzN4h0Na8D33E1j67wst_82QvONyLp-hp0OsiM_iGJ-jR7Z9gY7HkWx6fYKnu7tT3Qk-xuMdDfX6JWq-NZ3xCZprPHd4cvZrQs7n14ThUbegAldtHZ5y_NOCsm77EMFCh53F39tZoxtfhwfrNfapIGQa6_ksVj2-bpb-0gmeGJ-zA67vFfp9eTE9vyJDYQVihGQ90UqAHhhTtZHKVFpBhK3qzHCdaj9nnWkNzo1RQ1NnGbh8avKK5dw6p4pc89fooJ239i3CNYVuJKtSa7jg2mqdukxySbXLbCWLBH3ZrHdpBtZxX_zitgT04XVT7nSToE9b2UXk2rhX6qtX21bC82OHD2A15WA15f-sJkGHG6WXw6btSs-mBvEOxFgJOto2w3bz_1Cq1s5XQcZjMgicE_Qm2sh2JBzApr_YmyC5Zz17Q91vaZtZoPQuPKkRL949xNzeoyfMJ94EfspDdNAvV_YDemz-9E23_Bj2yV9YGRcS priority: 102 providerName: Directory of Open Access Journals
Title	Discovery of SARS-CoV-2 Nsp14 and Nsp16 Methyltransferase Inhibitors by High-Throughput Virtual Screening
URI	https://www.ncbi.nlm.nih.gov/pubmed/34959647 https://www.proquest.com/docview/2612812741 https://www.proquest.com/docview/2615118013 https://pubmed.ncbi.nlm.nih.gov/PMC8705538 https://doaj.org/article/6709c629556e44969006c3d0b961d7b0
Volume	14
WOSCitedRecordID	wos000737083000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: DOA dateStart: 20090101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M~E dateStart: 20040101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: BENPR dateStart: 20040101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: PIMPY dateStart: 20040101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest – providerCode: PRVPQU databaseName: Research Library customDbUrl: eissn: 1424-8247 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0057141 issn: 1424-8247 databaseCode: M2O dateStart: 20040101 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3db9MwELdYxwMvfDMCozICTUJatNhO4vgJbWMTk2iJ1jKVpyh2HBppSkrTIvW_5y5JW4omXniJEtuyTjnfl33-HSHveZ4JxiA60cZq1-c2cyEEE66SXs5ysFnGNDizX-RwGE0mKu423OourXKtExtFnVUG98hPEOoKjBEYwI-zny5WjcLT1a6Exh7ZR6Qyv0f2zy6G8fVaFweS-awFJRUQ3J_MpvANytoXO2aoQeu_y8X8O1PyD9Nz-eh_iX5MHnZOJz1tV8kTcs-WT8lR3KJWr47peHsJqz6mRzTe4lmvnpHiU1EbzPRc0Sqno9PrkXte3bicDusZ82laZs1bSAcWuH67aFxhmLC29KqcFrrAgj5UryjmlLjjtjDQbLmgN8Ucb6_QkcHkH7Chz8m3y4vx-We3q9DgGl_yhauVDwzlXGVGKpNqBa66ygIjtKfxp-lAa7CSnBnm5ZaD78BMmPJQ2DxXUajFC9Irq9K-JDRjMI3kqWeN8IW2Wnt5IIVkOg9sKiOHfFgzLDEdfDlW0bhNIIxB5iZb5jrk3WbsrAXtuHPUGfJ9MwKBtpuGav4j6eQ2QXg7E3IVBKH1fRUq0FJGZJ5WIcuk9hxyuOZ80kl_nWzZ7pC3m26QWzyMSUtbLZsxGNyBB-6Qg3aRbSgRELXiDWGHyJ3lt0Pqbk9ZTBts8AjRkUT06t9kvSYPOObmNBCWh6S3mC_tG3Lf_FoU9bxP9uQk6nei1G92KeA54F-hLb4axN9_A-WlLJA
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQIIX7pfAACNgEtKixXYS1w8IjY1p1bpS0W7aW4gdh0aaktK0oPwpfiPnJE1L0cTbHnjL5ciynM_nEp_zHULe8DQRjEF0oo3Vrs9t4kIIJlwlvZSlYLOMqXlme7Lf75yfq8EG-dXWwmBaZasTa0WdFAb_ke8i1RUYIzCAHybfXewahaerbQuNBhbHtvoJIVv5vnsA3_ct54efRvtH7qKrgGt8yWeuVj5MgnOVGKlMrBW4lyoJjNCexpRIHWgNmp0zw7zUcrB3zIQxD4VNU9UJtYBxr5HrPjKLYaog_9xq_kAynzUUqEIob3cyhnswDb5YM3p1b4DLHNq_8zL_MHSHd_63JbpLbi9carrX7IF7ZMPm98n2oOHkrnboaFViVu7QbTpYsXVXD0h2kJUG81grWqR0uPdl6O4XZy6n_XLCfBrnSX0V0hMLmL6Y1Y4-DFha2s3Hmc6wXRHVFcWMGXfUtD2azGf0LJtibQ4dGkxtAg_hITm9kmV4RDbzIrdPCE0YDCN57FkjfKGt1l4aSCGZTgMby45D3rUAicyCnB17hFxEEKQhmKIVmBzyeik7aShJLpX6iDhbSiCNeP2gmH6LFlopQvI-E3IVBKH1fRUq0MFGJJ5WIUuk9hyy1SItWui2MlrBzCGvlq9BK-FRU5zbYl7LYOgK8YVDHjegXs5EQEyO9c8OkWtwX5vq-ps8G9fM5x3kfhKdp_-e1kty82h00ot63f7xM3KLYxZSTda5RTZn07l9Tm6YH7OsnL6oty8lX696M_wGGcGE2w
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQIgX7pfAACNgEtKixnYS1w8IjZWKaqNUrJv2FmLHoZGmpDQtqH-NX8c5ubQUTbztgbdcLMtKPp_PJ_n8HUJe8TQRjEF2oo3Vrs9t4kIKJlwlvZSlwFnGVD6zR3I47J6dqdEW-dXuhUFZZRsTq0CdFAa_kXfQ6grICAiwkzayiFGv_2763cUKUvintS2nUUPk0C5_QvpWvh304F2_5rz_YXzw0W0qDLjGl3zuauXDgDhXiZHKxFrBUlMlgRHa0yiP1IHWEOU5M8xLLQfuYyaMeShsmqpuqAX0e4VclT6QMsoG-eeWBQLJfFbboQqhvM50AudAE77YIMCqTsBFi9u_NZp_kF7_1v_8uG6Tm81Sm-7Xc-MO2bL5XbI7qr26l3t0vN56Vu7RXTpau3gv75Gsl5UG9a1LWqT0eP_LsXtQnLqcDssp82mcJ9VRSD9ZwPr5vEoAoMPS0kE-yXSGZYyoXlJU0rjjuhzSdDGnp9kM9-zQY4OSJ1g53Ccnl_IYHpDtvMjtI0ITBt1IHnvWCF9oq7WXBlJIptPAxrLrkDctWCLTmLZj7ZDzCJI3BFa0BpZDXq7aTmurkgtbvUfMrVqgvXh1oZh9i5poFaGpnwm5CoLQ-r4KFcRmIxJPq5AlUnsO2WlRFzUxr4zWkHPIi9VtiFb4CyrObbGo2mBKC3mHQx7WAF-NRECujvuiHSI3oL8x1M07eTapHNG76Akluo__Pazn5DrMgehoMDx8Qm5wFCdVHp47ZHs-W9in5Jr5Mc_K2bNqJlPy9bLnwm8dJI2h
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Discovery+of+SARS-CoV-2+Nsp14+and+Nsp16+Methyltransferase+Inhibitors+by+High-Throughput+Virtual+Screening&rft.jtitle=Pharmaceuticals+%28Basel%2C+Switzerland%29&rft.au=Raitis+Bobrovs&rft.au=Kanepe%2C+Iveta&rft.au=Narvaiss%2C+Nauris&rft.au=Patetko%2C+Liene&rft.date=2021-11-30&rft.pub=MDPI+AG&rft.eissn=1424-8247&rft.volume=14&rft.issue=12&rft.spage=1243&rft_id=info:doi/10.3390%2Fph14121243&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1424-8247&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1424-8247&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1424-8247&client=summon